Chengdu Bett Pharmaceuticals will take the first imitation of hepatitis B god medicine.

Pharma Network September 25 - September 23, Chengdu Bett Pharmaceuticals to copy the four categories of reported fumarate propofol nofowe tablets into the administrative approval stage, the product developed by Gilead, as early as November 2016 was approved by the FDA for listing, 2019 global sales of $488 million.
the current domestic market only the original research products are on sale, 16 enterprises to the new classification of production.
source: The official website of the National Drug Administration, propofol nofovir (phosphate nofovir/tinofoviraraphenolamine), is a new nucleoside reverse transcriptase inhibitor developed by Gilead for the treatment of chronic hepatitis B.
the product was approved for listing by the FDA as early as November 10, 2016 and by the European EMA on January 9, 2017.
as an upgraded version of Ternofovir, propofol is highly antiviral, low-resistant, virtually non-renal toxicity, and better bone safety, with global sales of $488 million in 2019.
's propofol tynofowe was approved for entry into the domestic market in November 2018 and only the original product is currently on sale.
intranet data show that in 2019, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal propofol for Nofowe sales of more than 30 million yuan.
table: Fumarate propofol in the new classification of Nofowe tablets reported the situation Source: Minnet MED2.0 China Drug Review Database Minet data show that there are currently 16 domestic enterprises (by enterprise name) Applications for the listing of fumarate propofol to Novowe tablets were submitted in categories 3 or 4 imitations, of which Chengdu Bett Pharmaceuticals' products entered the administrative approval stage on September 23rd, and are expected to become the first generic drugs approved for the market.
.